Dramatic marketing claims are another warning sign
These effects go beyond weight loss to address broader health risks
Healthcare professionals prescribing Wegovy should conduct a thorough medical history before initiation, including assessment of: Previous or current neurological conditions History of pancreatitis or gallbladder disease Diabetic retinopathy (in patients with diabetes) Renal function Concurrent medications that may interact Regular monitoring during treatment should include: Assessment of weight loss progress and tolerability Blood glucose monitoring (particularly in patients with diabetes) Review of gastrointestinal symptoms and hydration status Evaluation of any new or worsening symptoms The European Medicines Agency (EMA) and MHRA require manufacturers to submit periodic safety update reports, which analyse all available safety data from clinical trials, post-marketing surveillance, and published literature
Patients already struggling with reduced appetite on Wegovy may benefit from monitoring calorie and protein intake more carefully after starting supplements
Important Note FDA-approved medications and diagnostic tools discussed in this article have specific indications, dosing, and monitoring requirements
In addition, toll-like receptor-4 knockout (TLR4KO) mice (1012 weeks of age
